Vir Biotechnology Inc (OQ:VIR)

Business Focus: Biotechnology & Medical Research

Apr 11, 2024 04:30 pm ET
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024.
Mar 05, 2024 08:05 am ET
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated. This includes over 60 participants in two additional cohorts – one evaluating tobevibart given every 2 weeks and the other evaluating the combination of tobevibart and elebsiran given every 4 weeks. Initial data are expected in the second quarter of 2024.
Feb 23, 2024 08:05 am ET
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of March:
Feb 22, 2024 04:05 pm ET
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
Feb 20, 2024 04:30 pm ET
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family. The Company has initiated a search for a successor.
Feb 01, 2024 04:05 pm ET
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter ended December 31, 2023, on February 22, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on February 22, 2024.
Dec 13, 2023 04:05 pm ET
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced strategic imperatives to focus its capital allocation on programs with the highest potential for patient impact and value creation. These are designed to optimize the Company’s cost structure by reducing the size of its workforce and the number of sites it operates.
Dec 06, 2023 04:05 pm ET
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, will present at the J.P. Morgan 2024 42nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET.
Nov 13, 2023 08:00 am ET
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential clinical impact that VIR-3434, an investigational monoclonal antibody (mAb), and VIR-2218, an investigational small interfering ribonucleic acid (siRNA), could have for chronic hepatitis delta (CHD) and chronic hepatitis B (CHB) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®. These include one late-breaking oral presentation and one late-breaking poster presentation.
Nov 10, 2023 08:00 am ET
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include one late-breaking poster presentation and one late-breaking oral presentation.
Nov 08, 2023 08:05 am ET
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. This is the first time in the 29-year history of the Deloitte Technology Fast 500 program that a company has topped the list for two consecutive years.
Nov 02, 2023 04:05 pm ET
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
Oct 30, 2023 08:00 am ET
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company’s research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will report to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company’s Executive Management Team.
Oct 12, 2023 04:05 pm ET
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a virtual fireside Q&A at the H.C. Wainwright 4th Annual...
Oct 11, 2023 08:00 am ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association...
Oct 05, 2023 04:30 pm ET
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023. The Company will host a conference call at 4:30 p.m....
Oct 03, 2023 07:59 am ET
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response...
Sep 27, 2023 01:00 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or "the Company") (NASDAQ:VIR) for violations of the securities laws.
Sep 20, 2023 08:00 am ET
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of VIR-1388, an investigational novel T cell vaccine for the prevention of...
Aug 29, 2023 04:30 pm ET
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of September: Morgan Stanley 21st Annual Global Healthcare Conference at the Sheraton New...
Aug 25, 2023 05:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or "the Company") (NASDAQ:VIR) for violations of the securities laws.
Aug 23, 2023 05:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 23, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or "the Company") (NASDAQ:VIR) for violations of the securities laws.
Aug 04, 2023 06:00 am ET
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or "the Company") (NASDAQ:VIR) for violations of the securities laws.
Aug 03, 2023 04:05 pm ET
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023. “Our strategy is to prioritize our monoclonal antibody platform, which has already yielded two...
Aug 03, 2023 06:00 am ET
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or "the Company") (NASDAQ:VIR) for violations of the securities laws.
Jul 26, 2023 04:05 pm ET
Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023. The Company will host a conference call at 4:30 p.m....
Jul 26, 2023 06:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or "the Company") (NASDAQ:VIR) for violations of the securities laws.
Jul 24, 2023 06:00 am ET
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or "the Company") (NASDAQ:VIR) for violations of the securities laws.
Jul 20, 2023 08:00 am ET
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy...
Jun 29, 2023 09:00 am ET
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company’s strategic...
Jun 24, 2023 05:30 am ET
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B and D virus (HBV and HDV) portfolio that were presented at the EASL™ (European Association for the Study of the Liver) Congress. Data presented in a...
Jun 07, 2023 02:13 am ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing both hepatitis B virus (HBV) and hepatitis D virus (HDV) have been accepted for presentation at...
Jun 05, 2023 04:05 pm ET
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June...
May 17, 2023 04:05 pm ET
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio...
May 15, 2023 08:00 am ET
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Company’s business development efforts,...
May 11, 2023 08:30 am ET
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 STRIVE sub-protocol clinical trial evaluating the safety and efficacy of regimens containing combinations of VIR-3434, VIR-2218,...
May 04, 2023 04:05 pm ET
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2023. “Vir is at an exciting inflection point with three critical Phase 2 data readouts for hepatitis B,...
May 03, 2023 04:05 pm ET
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, at 8:00 a.m. PT / 11:00 a.m....
May 02, 2023 09:00 am ET
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it received a new $10 million grant from the Bill & Melinda Gates Foundation to support Vir’s novel T cell vaccine development program. The new grant will support the Phase 1 clinical...
Apr 11, 2023 04:05 pm ET
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to participate in a fireside chat at the 22nd Annual Needham Virtual...
Mar 08, 2023 04:05 pm ET
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday,...
Feb 28, 2023 04:05 pm ET
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43rd Annual Health Care Conference...
Feb 23, 2023 04:05 pm ET
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022. “2022 was a seminal year for Vir. We remained on the front lines of the COVID-19...
Feb 22, 2023 08:30 am ET
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UK’s National Institute for Health and Care Excellence (NICE) provided positive final draft guidance recommending the use of sotrovimab, an investigational SARS-CoV-2 neutralizing...
Feb 16, 2023 04:05 pm ET
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023. The corporate update and...
Feb 16, 2023 08:30 am ET
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sung Lee as Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023. The appointment follows the resignation of Howard Horn, who will leave the...
Feb 13, 2023 04:45 pm ET
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the research collaboration agreement established with GSK in 2020 has been amended to reflect that Vir will continue its ongoing efforts to discover, develop and advance next-generation...
Jan 25, 2023 08:29 am ET
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023. The Company’s Board of Directors has appointed industry veteran Marianne De...
Jan 03, 2023 04:05 pm ET
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will highlight the Company’s expected 2023 catalysts and long-term growth strategy at the 41st Annual J.P. Morgan Healthcare Conference on...
Dec 21, 2022 08:00 am ET
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the...
Dec 15, 2022 10:26 am ET
Moore Kuehn, PLLC Encourages Investors of Vir Biotechnology, Inc. to Contact Law Firm
Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Vir Biotechnology, Inc. (NASDAQ: VIR) breached their fiduciary duties to shareholders. The investigation concerns potential...
Nov 16, 2022 08:30 am ET
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first on the 2022 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North...
Nov 10, 2022 02:36 pm ET
Moore Kuehn, PLLC Encourages Investors of Vir Biotechnology, Inc. to Contact Law Firm
NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Vir Biotechnology, Inc. (NASDAQ: VIR) breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Nov 06, 2022 10:35 am ET
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure. These data, plus health outcomes research, are being presented at the American Association for...
Nov 03, 2022 04:03 pm ET
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2022. “Throughout the quarter and into October, Vir achieved several important milestones that are...
Oct 31, 2022 04:05 pm ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical program have been accepted for presentation at the American Association for the Study of Liver Diseases...
Oct 28, 2022 06:06 pm ET
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022. The corporate update and financial...
Oct 18, 2022 08:00 am ET
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 PENINSULA (Prevention of Illness Due to Influenza A) trial evaluating VIR-2482 for the prevention of illness due to influenza A. This...
Oct 11, 2022 04:03 pm ET
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research, is scheduled to present at the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV)...
Oct 04, 2022 09:35 am ET
Thinking about buying stock in Inhibrx, Playtika, Poshmark, Vir Biotechnology, or Ferroglobe?
NEW YORK, Oct. 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INBX, PLTK, POSH, VIR, and GSM.
Oct 04, 2022 08:00 am ET
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response...
Sep 22, 2022 08:00 am ET
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic...
Sep 06, 2022 04:05 pm ET
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, at 4:05 p.m. ET. A live webcast of the fire side...
Aug 31, 2022 09:55 am ET
Moore Kuehn, PLLC Encourages Investors of Vir Biotechnology, Inc. to Contact Law Firm
Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Vir Biotechnology, Inc. (NASDAQ: VIR) breached their fiduciary duties to shareholders. The investigation concerns potential...
Aug 09, 2022 04:02 pm ET
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2022. “Vir closed the second quarter with a balance sheet that we believe is sufficient to fund the...
Jul 21, 2022 04:05 pm ET
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022. The corporate update and financial results will...
Jul 14, 2022 08:30 am ET
Vir Biotechnology Announces Transition of Chief Scientific Officer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Herbert “Skip” Virgin, M.D., Ph.D., Vir’s executive vice president, research and chief scientific officer, will step down effective August 31, 2022 to pursue a new position as chief medical...
Jun 25, 2022 07:00 am ET
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of...
Jun 08, 2022 07:33 am ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster presentations at the International Liver Congress™ 2022 (ILC), the...
May 18, 2022 04:03 pm ET
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20, 2022, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio...
May 05, 2022 04:07 pm ET
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. “In the first quarter, we recorded $1.2 billion of sotrovimab collaboration revenue and remained...
Apr 27, 2022 08:39 am ET
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will review its robust hepatitis portfolio, including initial data from the first cohort of the MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial...
Apr 23, 2022 03:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
NEW YORK, April 23, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("VIR" or the "Company") (NASDAQ: VIR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Apr 21, 2022 04:05 pm ET
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022. The update will be provided via a press release...
Apr 19, 2022 09:17 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir Biotechnology, Inc. - VIR
Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. (“VIR” or the “Company”) (NASDAQ: VIR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Apr 15, 2022 09:10 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR
Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. (“VIR” or the “Company”) (NASDAQ: VIR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Apr 13, 2022 04:02 pm ET
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment community on Wednesday, April 27, from 12:00 – 2:00 p.m. ET. Vir’s Hepatitis Portfolio R&D Day will review...
Apr 11, 2022 08:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biotechnology, Inc. - VIR
NEW YORK, April 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("VIR" or the "Company") (NASDAQ: VIR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Apr 06, 2022 12:14 pm ET
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that a team of three company scientists were named one of the winners of the Pediatric COVID-19 Data Challenge, sponsored by the Biomedical Advanced Research and Development Authority (BARDA)...
Apr 05, 2022 03:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Vir Biotechnology, Inc. – VIR
Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. (“VIR” or the “Company”) (NASDAQ: VIR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Apr 04, 2022 04:02 pm ET
Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on Monday, April 11, at 11:00 a.m. ET. The conference will be held virtually. A live...
Mar 29, 2022 06:43 pm ET
Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P SmallCap 600
NEW YORK, March 29, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Camden Property Trust (NYSE: CPT) will replace People's United Financial Inc. (NASD: PBCT) in the S&P 500, S&P SmallCap 600 constituent Matador Resources Co. (NYSE: MTDR) will replace Camden Property Trust in the S&P MidCap 400 and Vir Biotechnology, Inc. (NASD: VIR) will replace Matador Resources in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 4.  S&P 500 constituent M&T Bank Corp. (NYSE: MTB) is acquiring People's United Financial in a deal expected to be compl
Mar 25, 2022 04:04 pm ET
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal...
Mar 02, 2022 04:02 pm ET
Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42nd Annual Cowen Healthcare Conference on Wednesday, March 9, at 10:30 a.m. ET. The conference will be held...
Feb 24, 2022 04:03 pm ET
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. “2021 was a transformative year in which we delivered our first blockbuster...
Feb 10, 2022 04:02 pm ET
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022. The update will be...
Feb 10, 2022 01:24 am ET
Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that preclinical data suggest that sotrovimab, an investigational monoclonal antibody authorized for emergency use in the United States and developed in conjunction with GlaxoSmithKline, retains...
Feb 08, 2022 06:00 am ET
Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global, effective March 2, 2022. Reporting to Vir’s Chief Executive Officer George Scangos,...
Jan 13, 2022 09:05 am ET
Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an expansion of its partnership with the Bill & Melinda Gates Foundation to include the advancement of innovative platform technologies in the development of broadly neutralizing antibodies...
Jan 13, 2022 09:02 am ET
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the US Food and Drug Administration (FDA) requesting an amendment to the Emergency Use Authorization (EUA) for...
Jan 13, 2022 08:31 am ET
Thinking about trading options or stock in KB Home, Vir Biotechnology, Applied Materials, Take-Two Interactive, or Nio?
NEW YORK, Jan. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KBH, VIR, AMAT, TTWO, and NIO.
Jan 11, 2022 07:30 am ET
Thinking about buying stock in Accolade, Vir Biotechnology, bluebird bio, Energy Focus, or Intercept Pharmaceuticals?
NEW YORK, Jan. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACCD, VIR, BLUE, EFOI, and ICPT.
Jan 11, 2022 07:12 am ET
GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US government will purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of...
Jan 04, 2022 04:02 pm ET
Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 p.m. ET. The conference will be held...
Dec 31, 2021 08:46 am ET
Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical research published to the preprint server bioRxiv, describing the structural basis and magnitude by which the new SARS-CoV-2 Omicron variant (B.1.1.529) evades antibody mediated...
Dec 22, 2021 08:31 am ET
Thinking about trading options or stock in Vir Biotechnology, CarMax, Nike, Paychex, or Citrix Systems?
NEW YORK, Dec. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, KMX, NKE, PAYX, and CTXS.
Dec 20, 2021 08:31 am ET
Thinking about trading options or stock in Moderna, Vir Biotechnology, BioNTech, Cerner Corp, or Apple?
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, VIR, BNTX, CERN, and AAPL.
Dec 17, 2021 08:31 am ET
Thinking about trading options or stock in FedEx, Vir Biotechnology, AT&T, Roku, or Rivian Automotive?
NEW YORK, Dec. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FDX, VIR, T, ROKU, and RIVN.
Dec 17, 2021 08:16 am ET
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Commission (EC) has granted marketing authorization to Xevudy (sotrovimab) for the early treatment of COVID-19. Sotrovimab is now...
Dec 16, 2021 08:31 am ET
Thinking about trading options or stock in Tesla, Accenture, AMC Entertainment, Microsoft, or Vir Biotechnology?
NEW YORK, Dec. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, ACN, AMC, MSFT, and VIR.
Dec 15, 2021 08:31 am ET
Thinking about trading options or stock in Apple, Vir Biotechnology, Centene Corp, Pfizer, or GameStop?
NEW YORK, Dec. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, VIR, CNC, PFE, and GME.
Dec 14, 2021 04:39 pm ET
Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-E
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant (B.1.1.529). A significant...
Dec 14, 2021 08:31 am ET
Thinking about trading options or stock in Vir Biotechnology, Pfizer, Apple, Tesla, or AMC Entertainment?
NEW YORK, Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, PFE, AAPL, TSLA, and AMC.
Dec 09, 2021 08:30 am ET
Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating novel therapeutic combinations for the treatment of chronic hepatitis B virus (HBV) infection. The multi-arm trial,...
Dec 07, 2021 03:55 am ET
Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant
Vir Biotechnology, Inc. (Nasdaq: VIR) announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new data that demonstrates sotrovimab retains activity against the full combination of mutations in the...
Dec 07, 2021 03:48 am ET
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an update to preclinical data on bioRxiv1, a preprint server, demonstrating that sotrovimab, an investigational monoclonal antibody, retains in vitro...
Dec 02, 2021 08:31 am ET
Thinking about trading options or stock in Vir Biotechnology, Boeing, AMC Entertainment, Peloton Interactive, or Chesapeake Energy?
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, BA, AMC, PTON, and CHK.
Dec 02, 2021 02:07 am ET
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity...
Nov 30, 2021 08:31 am ET
Thinking about trading options or stock in Vir Biotechnology, Novavax, Applied Materials, Pfizer, or Salesforce?
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, NVAX, AMAT, PFE, and CRM.
Nov 26, 2021 08:31 am ET
Thinking about buying stock in Vir Biotechnology, BioNTech, Cars.com, Teladoc Health, or Pfizer?
NEW YORK, Nov. 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, BNTX, CARS, TDOC, and PFE.
Nov 17, 2021 07:37 am ET
Thinking about buying stock in 17 Education & Technology, Progenity, Canoo, Vir Biotechnology, or Zosano Pharma?
NEW YORK, Nov. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for YQ, PROG, GOEV, VIR, and ZSAN.
Nov 17, 2021 06:42 am ET
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced US government contracts totaling approximately $1 billion1 (USD) to purchase sotrovimab, an investigational monoclonal antibody for the early treatment of...
Nov 12, 2021 08:00 am ET
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the Company’s broad hepatitis B virus (HBV) portfolio focused on achieving a functional cure for chronic HBV infection. Preliminary results from an ongoing Phase 2 clinical trial...
Nov 12, 2021 07:10 am ET
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced headline data from the randomized, multi-center, open-label COMET-TAIL Phase 3 trial, which achieved its primary endpoint, demonstrating intramuscular...
Nov 04, 2021 04:05 pm ET
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. “The third quarter was both rewarding and financially important for Vir. We made significant...
Nov 04, 2021 08:14 am ET
Section 32 Raises $740 Million Venture Fund
SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the app
Oct 21, 2021 04:05 pm ET
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021. The update will be provided via a press...
Oct 15, 2021 08:30 am ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American...
Oct 06, 2021 04:05 pm ET
Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference on Wednesday, Oct. 13, at 9:30 a.m. PT / 12:30...
Sep 30, 2021 04:05 pm ET
Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference on Wednesday, Oct. 6, at 11:30 a.m. PT / 2:30...
Sep 30, 2021 09:31 am ET
Thinking about trading options or stock in Vir Biotechnology, AutoZone, Netflix, Tesla, or Lucid Group?
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, AZO, NFLX, TSLA, and LCID.
Sep 08, 2021 04:05 pm ET
Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, Sept. 14 at 9:30 a.m....
Sep 07, 2021 04:05 pm ET
Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, Sept. 13, at 4:00 a.m. PT / 7:00 a.m. ET. A live...
Aug 23, 2021 08:30 am ET
Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product, sotrovimab, developed in partnership with GlaxoSmithKline (GSK). This announcement follows news shared...
Aug 06, 2021 09:31 am ET
Thinking about trading options or stock in Groupon, Plug Power, Vir Biotechnology, Albemarle Corp, or Paycom Software?
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRPN, PLUG, VIR, ALB, and PAYC.
Aug 05, 2021 04:05 pm ET
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. “Vir made strong progress this quarter across our extensive infectious disease...
Jul 28, 2021 06:20 am ET
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an investigational single dose...
Jul 22, 2021 04:05 pm ET
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021. The update will be provided via a press release...
Jul 15, 2021 08:30 am ET
Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial evaluating VIR-2218 together with VIR-3434 for the treatment of...
Jun 25, 2021 08:50 am ET
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection. The results, which demonstrate...
Jun 21, 2021 07:06 am ET
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced final, confirmatory results from the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial demonstrating that...
Jun 14, 2021 08:00 am ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting data from its hepatitis B clinical program have been accepted for two oral and two poster presentations at the European Association for the Study of the Liver...
Jun 02, 2021 04:05 pm ET
Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9th at 12:00 pm...
May 26, 2021 06:57 pm ET
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for sotrovimab (previously VIR-7831), an investigational...
May 21, 2021 08:04 am ET
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion following the referral of sotrovimab to the CHMP under...
May 10, 2021 04:05 pm ET
Vir Biotechnology Reminds Stockholders of 2021 Annual General Meeting Details
Vir Biotechnology, Inc. (Nasdaq: VIR) reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on Thursday, May 20, 2021, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast....
May 07, 2021 05:53 am ET
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) has started a rolling review of data on sotrovimab (previously VIR-7831), an investigational dual-action...
May 06, 2021 04:05 pm ET
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. “We’ve had an active start to the year, achieving significant clinical and collaboration milestones...
Apr 22, 2021 04:01 pm ET
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021. The update will be provided via a press release...
Apr 21, 2021 08:00 am ET
Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Brii Biosciences (“Brii Bio”), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating BRII-835 (VIR-2218), an investigational small...
Apr 21, 2021 08:00 am ET
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid (siRNA) targeting hepatitis B virus (HBV), in combination with BRII-179 (VBI-2601), an investigational HBV immunotherapeutic, for the treatment of chronic HBV infection. This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.
Apr 21, 2021 08:00 am ET
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid (siRNA) targeting hepatitis B virus (HBV), in combination with BRII-179 (VBI-2601), an investigational HBV immunotherapeutic, for the treatment of chronic HBV infection. This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.
Apr 15, 2021 09:50 am ET
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody, for...
Apr 08, 2021 08:30 am ET
Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new preclinical research highlighting novel mechanisms by which SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) enters host cells and identifying how auxiliary...
Apr 06, 2021 04:01 pm ET
Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13th at 8:45 am PT /...
Apr 05, 2021 08:00 am ET
Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical research demonstrating the ability of VIR-7831, the company’s investigational SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) monoclonal antibody (mAb), to maintain...
Mar 29, 2021 08:30 am ET
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19....
Mar 26, 2021 08:30 am ET
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for VIR-7831 (GSK4182136), an...
Mar 10, 2021 08:22 pm ET
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that an Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care...
Mar 03, 2021 09:00 am ET
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today provided an update on the VIR-7831 (GSK4182136) arm of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines...
Feb 25, 2021 04:01 pm ET
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020. “Vir closed 2020 delivering strong progress across our entire development...
Feb 25, 2021 08:31 am ET
Thinking about trading options or stock in Tandem Diabetes Care, Revolve Group, Callon Petroleum, Vir Biotechnology, or T-Mobile?
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNDM, RVLV, CPE, VIR, and TMUS.
Feb 17, 2021 08:31 am ET
Thinking about trading options or stock in Vir Biotechnology, Verizon, Nektar Therapeutics, Chevron, or Estee Lauder?
NEW YORK, Feb. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, VZ, NKTR, CVX, and EL.
Feb 17, 2021 07:04 am ET
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and...
Feb 11, 2021 04:01 pm ET
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021. The update will be provided...
Feb 01, 2021 08:31 am ET
Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics?
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKTR, PFE, AZN, VIR, and ESPR.
Feb 01, 2021 08:00 am ET
Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new research characterizing a novel site of vulnerability on the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) spike protein – specifically the N-terminal...
Jan 29, 2021 08:31 am ET
Thinking about trading options or stock in Moderna, Vir Biotechnology, Skyworks Solutions, BioNTech, or Western Digital Corp?
NEW YORK, Jan. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, VIR, SWKS, BNTX, and WDC.
Jan 28, 2021 07:30 am ET
Thinking about buying stock in Sundial Growers, American Airlines, GameStop, Vir Biotechnology, or Carnival Corp?
NEW YORK, Jan. 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, AAL, GME, VIR, and CCL.
Jan 27, 2021 06:45 am ET
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate...
Jan 27, 2021 05:45 am ET
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein. This unique collaboratio
Jan 26, 2021 08:00 am ET
Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced initial topline data from its ongoing trial of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection. Data from the first blinded cohort of eight patients, two of whom received...
Jan 21, 2021 08:31 am ET
Thinking about trading options or stock in Vir Biotechnology, Ford Motor, Boeing, GrubHub, or Taiwan Semiconductor?
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, F, BA, GRUB, and TSM.
Jan 20, 2021 08:31 am ET
Thinking about trading options or stock in Netflix, Vir Biotechnology, Alibaba, Niu Technologies, or Advanced Micro Devices?
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NFLX, VIR, BABA, NIU, and AMD.
Jan 12, 2021 08:00 am ET
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).
Jan 12, 2021 08:00 am ET
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure...
Jan 12, 2021 03:00 am ET
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial....
Jan 06, 2021 08:00 am ET
Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, announced that the first patient was dosed in late December 2020 in a Phase 1 clinical trial of VIR-1111, an...
Jan 05, 2021 08:00 am ET
Vir Biotechnology to Present at 39th Annual J.P. Morgan Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., chief executive officer will virtually present at the 39th Annual...
Dec 17, 2020 04:01 pm ET
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and...
Dec 10, 2020 08:00 am ET
Vir Biotechnology Appoints Jeffrey Hatfield to its Board of Directors
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeffrey Hatfield, an accomplished industry executive with more than three decades of commercial experience, to its Board of Directors. “We are pleased to welcome Jeff to the...
Nov 10, 2020 04:01 pm ET
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the third quarter ended September 30,...
Nov 06, 2020 08:00 am ET
Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new research demonstrating that the immunodominant SARS-CoV-2 receptor binding motif (RBM) is the least conserved region in the SARS-CoV-2 spike protein, allowing for the...
Oct 27, 2020 04:01 pm ET
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the third quarter...
Oct 22, 2020 09:31 am ET
Thinking about buying stock in Vir Biotechnology, Intel Corp, Switchback Energy Acquisition, Helix Energy Solutions, or MGM Resorts?
NEW YORK, Oct. 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, INTC, SBE, HLX, and MGM.
Oct 21, 2020 08:00 am ET
Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020
Vir Biotechnology, Inc. (NASDAQ: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the presentation of preclinical and Phase 1 data demonstrating the broad neutralizing...
Oct 13, 2020 04:01 pm ET
Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that Phil Pang, M.D., Ph.D., Chief Medical Officer of Vir, and Vasant Jadhav, Ph.D., Vice President, Research at Alnylam, will jointly...
Oct 09, 2020 08:00 am ET
Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral Infection
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of preclinical research in an influenza animal model highlighting a new mechanism for enhancing the efficacy of monoclonal antibodies to treat viral infection and induce a...
Oct 06, 2020 08:18 am ET
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study evaluating VIR-7831 for the...
Sep 24, 2020 08:00 am ET
Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the online publication of new research characterizing differences in antibody responses to SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). This analysis, which is the largest to...
Sep 09, 2020 04:10 pm ET
Vir Biotechnology to Present at Cantor Global Virtual Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., chief medical officer of Vir will present at the Cantor Global...
Sep 08, 2020 04:01 pm ET
Vir Biotechnology to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., chief medical officer of Vir will virtually present at the H.C....
Sep 01, 2020 04:01 pm ET
Vir Biotechnology Appoints Janet Napolitano to its Board of Directors
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Janet Napolitano to its board of directors. Napolitano brings a breadth of leadership experience in both the public and private sectors to the organization. In addition to her...
Aug 31, 2020 08:00 am ET
Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute...
Aug 20, 2020 08:00 am ET
Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress™
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that data from its VIR-2218 clinical program will be featured at the European Association for...
Aug 11, 2020 04:01 pm ET
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020....
Jul 28, 2020 04:01 pm ET
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2020 Financial Results on August 11, 2020
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the second quarter...
Jul 10, 2020 04:02 pm ET
Vir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Elliott Sigal, M.D., Ph.D., to its board of directors. Dr. Sigal formerly served as Executive Vice President, Chief Scientific Officer and President of Bristol-Myers Squibb...
Jul 10, 2020 04:01 pm ET
Vir Biotechnology Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the closing of its previously announced underwritten public offering of 8,214,285 shares of...
Jul 07, 2020 10:25 pm ET
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the pricing of its previously announced underwritten public offering of 7,142,857 shares of...
Jul 06, 2020 07:00 am ET
Vir Biotechnology Announces Proposed Public Offering of Common Stock
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, today announced that it has filed a registration...
May 29, 2020 08:00 am ET
Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that is has finalized a process development and manufacturing agreement with Biogen Inc. (Nasdaq: BIIB) based on the letter of intent that the companies announced in March. Under the agreement...
May 27, 2020 08:00 am ET
Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the initiation of a Phase 1 clinical trial of VIR-3434, an investigational monoclonal antibody that neutralizes hepatitis B virus (HBV) and has been engineered to potentially also act as a...
May 18, 2020 09:31 am ET
Thinking about trading stocks and options in Moderna, Vir Biotechnology, Scientific Games, American Airlines, or MGM Resorts?
NEW YORK, May 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, VIR, SGMS, AAL, and MGM.
May 18, 2020 05:05 am ET
Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of research findings from the company’s efforts to develop therapeutics for COVID-19 in the May 18, 2020 issue of the journal Nature. The paper, entitled “Cross-neutralization of...
May 12, 2020 04:01 pm ET
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020....
May 08, 2020 04:01 pm ET
Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
Vir Biotechnology, Inc. (Nasdaq: VIR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and...
May 07, 2020 04:01 pm ET
Vir Biotechnology to Present at BofA Securities 2020 Health Care Conference
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., Chief Executive Officer will virtually present at the BofA...
May 04, 2020 07:30 am ET
Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19
Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced the selection of a development candidate (DC) for VIR-2703 (also referred to as ALN-COV), an investigational RNAi therapeutic targeting the SARS-CoV-2 genome. The companies plan to soon meet with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to discuss a potential accelerated path for filing an Investigational New Drug (IND) or IND equivalent application at or around year-end 2020, less than a year since program initiation. The companies plan to advance VIR-2703
Apr 28, 2020 08:00 am ET
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2020 Financial Results on May 12, 2020
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the first quarter...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.